These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22917635)

  • 1. Comment on "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
    Angelico F; Del Ben M; Pignatelli P; Violi F
    Dig Liver Dis; 2013 Jan; 45(1):81-2. PubMed ID: 22917635
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Dig Liver Dis; 2013 Jan; 45(1):82-3. PubMed ID: 23058851
    [No Abstract]   [Full Text] [Related]  

  • 3. Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
    Yamagishi S
    Dig Liver Dis; 2013 Jan; 45(1):82. PubMed ID: 22909420
    [No Abstract]   [Full Text] [Related]  

  • 4. Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
    Yamagishi S; Maeda S; Hyogo H
    Dig Liver Dis; 2013 Jan; 45(1):83-4. PubMed ID: 23099228
    [No Abstract]   [Full Text] [Related]  

  • 5. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis?
    Lonardo A; Loria P
    Dig Liver Dis; 2012 Jun; 44(6):451-2. PubMed ID: 22487461
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
    Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
    Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
    Gómez-Domínguez E; Gisbert JP; Moreno-Monteagudo JA; García-Buey L; Moreno-Otero R
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1643-7. PubMed ID: 16696815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
    Kiyici M; Gulten M; Gurel S; Nak SG; Dolar E; Savci G; Adim SB; Yerci O; Memik F
    Can J Gastroenterol; 2003 Dec; 17(12):713-8. PubMed ID: 14679419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piriformis muscle syndrome: an unusual adverse effect of atorvastatin.
    Hamdi W; Ghannouchi MM; Kaffel D; Kchir MM
    J Clin Rheumatol; 2013 Apr; 19(3):156-7. PubMed ID: 23519180
    [No Abstract]   [Full Text] [Related]  

  • 11. [Atorvastatin in treatment of patients with coronary heart disease and dislipidemiya and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA].
    Mareev VIu; Belenkov IuN; Oganov RG; Barbik-Zhagar B
    Kardiologiia; 2008; 48(11):4-13. PubMed ID: 19076074
    [No Abstract]   [Full Text] [Related]  

  • 12. A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.
    Lee CW; Baek SH; Hong TJ; Choi YJ; Kim YJ; Ahn TH; Ihm SH; Bae JH; Hong SJ; Kim DI; Ahn YK; Hur SH; Park DG; Choi DJ; Lee SU; Kim BS; Ryu KH; Jang YS; Lee SH; Seung KB; Kim HS
    Cardiovasc Drugs Ther; 2010 Apr; 24(2):181-8. PubMed ID: 20383571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effective cholesterol and triglyceride lowering with atorvastatin].
    Internist (Berl); 1996 Aug; 37(8 Suppl Effektive):1-8. PubMed ID: 9404527
    [No Abstract]   [Full Text] [Related]  

  • 14. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
    Kimura Y; Hyogo H; Yamagishi S; Takeuchi M; Ishitobi T; Nabeshima Y; Arihiro K; Chayama K
    J Gastroenterol; 2010 Jul; 45(7):750-7. PubMed ID: 20112031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More on atorvastatin and fibrinogen.
    Otto C; Schwandt P
    Atherosclerosis; 2000 Aug; 151(2):591-2. PubMed ID: 10944081
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
    Ogata N; Fujimori S; Oka Y; Kaneko K
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):321-4. PubMed ID: 20544514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive LDL-cholesterol lowering with atorvastatin results in regression of atherosclerosis.
    Cardiovasc J S Afr; 2001; 12(1):56. PubMed ID: 11474689
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid-lowering with atorvastatin improves tissue characteristics of carotid plaque.
    Katakami N; Sakamoto K; Kaneto H; Matsuhisa M; Hori M; Yamasaki Y; Kosugi K; Waki H
    Atherosclerosis; 2005 Dec; 183(2):369-71. PubMed ID: 16162349
    [No Abstract]   [Full Text] [Related]  

  • 20. [Medical management of primary nonalcoholic fatty liver disease].
    Moreno Sánchez D
    Med Clin (Barc); 2005 Jun; 125(3):108-16. PubMed ID: 15989845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.